STAGE III PROSTATE CANCER AJCC V7
Clinical trials for STAGE III PROSTATE CANCER AJCC V7 explained in plain language.
Never miss a new study
Get alerted when new STAGE III PROSTATE CANCER AJCC V7 trials appear
Sign up with your email to follow new studies for STAGE III PROSTATE CANCER AJCC V7, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental combo targets cancer cell recycling in Late-Stage tumors
Disease control OngoingThis early-phase trial tests the safety and best dose of two drugs—MK-2206 and hydroxychloroquine—given together to people with advanced solid tumors, melanoma, prostate, or kidney cancer. The goal is to see if blocking a process called autophagy can help kill more cancer cells. …
Matched conditions: STAGE III PROSTATE CANCER AJCC V7
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 04:13 UTC
-
Could a Two-Drug combo stop prostate cancer from returning?
Disease control OngoingThis study looks at men whose prostate cancer has returned after initial treatment, shown by rising PSA levels. It tests whether adding an experimental drug (MK-2206) to the standard hormone therapy bicalutamide works better than bicalutamide alone. The goal is to see if the comb…
Matched conditions: STAGE III PROSTATE CANCER AJCC V7
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:53 UTC